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Abstract
Purpose: To investigate the incidence, radiographic findings, and the time course for the appearence of lung metastases from
primary extremity sarcoma.
Patients and methods: Four-hundred patients with extremity sarcoma were evaluated retrospectively for lung metastases.
Multiple clinical factors were analyzed for possible influence on the metastases-free interval and subsequent metastases
development. Radiographic findings of metastases were also reviewed.
Results: Ninety of 400 patients (23%) developed lung metastases. Median time from presentation to detection of metastasis
was 8.0 1.1 months (95% CI: 6.02–9.98). More than 75% of patients developed metastases within 1 year after presentation
of the primary sarcoma. As disease grade increased, the metastases-free intervals shortened significantly. Histologically,
synoviosarcoma and osteogenic sarcoma were more often associated with the development of lung metastases. In this
subgroup, 54 patients (60%), the presence of solitary (11) or multiple (43) nodular metastases was the only radiological
finding. In 36 of 90 patients (40%), parenchymal mass, pleural effusion, hilar lymphadenopathy and pneumothorax were
found.
Conclusions: Twenty-three percent of patients in our study developed lung metastases. As the grade of the disease increased,
metastases-free intervals are shortened. Although it has been reported that lung metastases in patients with extremity
sarcomas may present as solitary or multiple nodules in earlier trials with radiographic screening methods, the current review
of 400 patients found that a substantial number of patients may present radiological appearances other than nodular
formations.
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Introduction
Primary extremity sarcomas are unique in that, in the
majority of cases, early metastases are confined to the
lungs. Patients with extremity sarcomas are more
likely to have distant metastatic disease as their initial
site of recurrence, whereas those with retroperitoneal
and visceral sarcomas tend to have local recurrence.
1
Consequently, patients with primary soft-tissue
sarcoma (STS) in an extremity tend to develop
pulmonary metastases more frequently than those
patients with sarcomas located in other sites.
2,3
Approximately 20% of patients with extremity STS
will develop isolated pulmonary metastases during
the course of their disease.
4
Although considerable progress has been made in
both chemotherapy and surgical treatment of extre-
mity sarcoma, pulmonary metastases in these
patients remain a major cause of mortality. Since
the diagnosis of pulmonary metastases significantly
effects the outcome of treatment and prognosis,
detecting such pulmonary metastases is vitally
important.
5 Currently, the characteristics of the
histological and radiographic findings, the relation-
ship between these findings, and the subsequent
clinical course of the pulmonary metastases remains
largely unknown.
In the present study, we have analysed retro-
spective data relevant to pulmonary metastases
in a large series of adult patients with extremity
sarcomas. We have attempted to evaluate the true
incidence, the time of occurrence, and radiographic
appearance of pulmonary metastases from extremity
sarcomas.
Patients and methods
For this study, we included all adult patients
(age >16 years old) with a primary extremity
sarcoma who were admitted and treated at the
Cancer Research Hospital (Ankara, Turkey) from
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interval, 400 patients with primary extremity sarco-
mas were evaluated. Of these, 90 patients developed
lung metastases. These patients comprise the study
group for this report. We reviewed the chest radio-
graphs from the initial diagnosis at the time of the
primary tumour and chest radiographs and computed
tomography (CT) performed at time of metastases.
All radiographs were reviewed independently by at
least two of the authors.
Patients with extremity sarcoma were followed up
by routine postoperative chest X-rays and CT
scanning obtained every 4 months for the first
2 years. During the third through fifth follow-up
years, patients received chest X-ray and CT scans
every6months. After5years postoperatively,patients
were followed-up by yearly CT scans. All CT scans
(General Electric Sytec 4000i, Milwaukee, USA)
were obtained with abutting 5- or 10-mm sections
through the lungs. The radiographic findings of lung
metastases were evaluated. The data were obtained
from the first positive chest radiographs and CT.
Morphological characterization of the pulmonary
metastases included a measurement of the diameter
of the largest mass, the determination of the total
number of lesions and the description of their
appearance. In this study, pulmonary nodules were
considered to be <3cm in diameter. Parenchymal
mass was considered to be >3cm in diameter, with
irregular contour. We also looked for a smooth or
spiculated contour, the presence or absence of
cavitation and other associated features such as
calcification, hilar and mediastinal adenopathy or
pleural effusion. If a solitary nodule or mass was
present on the first abnormal radiography, confirma-
tion of metastatic disease was obtained by biopsy
and/or surgical exploration. In cases in which clinical
evidence for a second primary tumour could not be
found, the presence of more than one parencyhmal
nodule was considered metastatic, and originating
from the extremity sarcoma.
The histopathological findings, including subtypes
and grades, were reviewed and diagnoses were
confirmed by an experienced author. We assessed
the metastases-free interval. Multiple clinical factors
were analysed for possible influence on the meta-
stases-free interval and subsequent metastases devel-
opment. Factors included patient age, gender, the
grading at initial presentation, histopathology, the
location (upper or lower extremity) and treatment
(preoperative chemotherapy, preoperative radio-
therapy, postoperative chemotherapy, postoperative
radiotherapy). Patients who had  1 year between
diagnosis of the primary tumor and diagnosis of lung
metastases were compared with patients who had a
metastases-free interval of >1 year. One year was
chosen, since more than 75% of patients developed
lung metastases within 1 year after presentation of
the primary sarcoma.
Statistical analysis
Statistical analyses and descriptive tables were made
by computer software (SPSS version 7.5). The
comparison of sarcoma subgroups was made using
chi-square tests. The metastases-free intervals for the
groups were calculated with Kaplan–Meier survival
analyses.
6 The comparison of the survival rates of all
three grades were calculated with the log-rank test.
Stepwise logistic regression analysis was performed
to determine the influence of specific factors on the
metastases-free interval. In all analyses, P<0.05 was
considered statistically significant.
Results
The median age was 43 years (range 16–79 years).
The median length of follow-up after diagnosis
of the primary extremity sarcoma was 26.1 months.
The median time elapsed from presentation of
extremity sarcoma to detection of subsequent lung
metastases was 8.0 1.01 months (95% CI: 6.02–
9.98). Within 1 year following presentation, more
than 75% of the patients developed lung metastases.
We have analysed the relationship between the
grade of primary tumours and the median time
elapsed from presentation to detection of lung
metastases. The median time for developing pul-
monary metastases was 14 7.3 (95% CI: 0–28.4),
11 0.78 (95% CI: 9.48–12.52) and 4 0.88 (95%
CI: 2.28–5.72) months in patients with grade I, II
and III, respectively. The summary of the results
on the grade of the primary tumours is presented
in Table 1. The metastases-free intervals lessened
significantly as the disease grade increased
(P<0.001). Results indicating the time elapsed from
presentation to detection of lung metastases for
each grade are presented in Fig. 1. The results of
multivariate logistic regression analysis investigating
influence of clinical factors on metastases-free inter-
val are shown in Table 2. Results indicated that only
tumour grade was significant (P¼0.003).
Histopathological examination of the metastatic
specimens found a wide spectrum of different
histological types (Table 3). Analysis of the distri-
bution of primary histology demonstrated that the
most common type of extremity sarcoma was
malignant fibrous histiocytoma (MFH; 33.7%);
followed by liposarcoma (23.7%) and osteogenic
Table 1. Grade at presentation of
extremity sarcomas in the patients






64 N. Songu ¨r et al.sarcoma (10.5%). Synoviosarcoma and osteogenic
sarcoma were more often associated with the
development of pulmonary metastases than other
histological types (46 and 40.4%, respectively).
Radiological appearances
Evaluations of radiological appearence were based
on the chest radiographs and CTs of 90 patients
Fig. 1. The time course of the metastases-free intervals for each grade of disease.
Table 3. Summary of the results on histological types and the number of pulmonary metastases in 400 adult patients with
extremity sarcoma
With pulmonary
Histological type Overall n (%) Metastases n (%) P value
Malignant fibrous histiocytoma 135 (33.7) 20 (22.2) 0.022*
(Myxoid and pleiomorph) liposarcoma 95 (23.7) 14 (15.5) 0.077
Fibrosarcoma 16 (4) 6 (6.6) 0.32
Synoviosarcoma 13 (3.25) 6 (6.6) 0.16
Leiomyosarcoma 22 (5.5) 7 (7.7) 0.65
Rhabdomyosarcoma 26 (6.5) 9 (10) 0.42
Malignant schwannoma 19 (4.75) 7 (7.7) 0.3
Extraskeletal osteosarcoma 5 (1.25) 2 (2.2) 0.62
Extraskeletal chondrosarcoma 4 (1) 1 (1.1) 0.4
Hemangiopericytoma 3 (0.75) 1 (1.1) 0.66
Osteogenic Sarcoma 42 (10.5) 17 (18.8) 0.066
Total 400 90
*Indicates statistically significant difference at the level of <0.05.
Table 2. Multivariate logistic regression analysis of clinical factors on metastases-free interval
Variable  SE Wald P value OR %95 CI
Grade (II)  2.2714 0.9707 5.4755 0.0193 0.1031 0.0154–0.6915
Grade (III)  2.8759 0.9588 8.9973 0.0027 0.0564 0.0086–0.3691
SE, standard error; OR, odds ratio; CI, confidence interval.
Analysis of lung metastases 65with extremity sarcoma. CT examinations indicated
that in 54 of 90 patients (60%), metastases were
confined to the presence of solitary (11/90) or
multiple (43/90) nodular metastases. In 11 patients
with solitary metastases, all pulmonary nodules were
>5mm in diameter. In 43 patients with multiple
nodular metastases, the size of the nodules showed
significant variations. Of this subgroup, 32 patients
had nodules both greater and less than 5mm in
diameter. In seven patients, all metastases were
<5mm in diameter. In the remaining four patients,
all metastases were >5mm in diameter. Forty
percent of the metastases presented in different
radiological appearances other than nodular forma-
tions. The summary of the results on the radiological
manifestation of the metastatic findings is presented
in Table 4.
The distributions of the metastatic nodules in
chest radiographs and CTs were not uniform.
The metastases were most commonly located in the
peripheral and lower zones of the lung. All of the
patients with solitary metastases had STS (n¼11).
In seven of 11 patients, diagnosis was confirmed by
thoracotomy. The physical conditions of the remain-
ing four patients prevented surgical exploration, and
follow-up CTs indicated disease progression despite
the chemotheraphy. As the radiographic appearance
of lung metastases, patients with osteogenic sarcoma
had parenchymatous or subpleural nodules, which
were often ossified. All masses had smooth borders
with no cavitation. In 14 patients, pleural effusions
were also noted. Parenchymal lesions were based
on pleura. Pleural effusions were found as isolated
radiographic findings in two of the patients. The
diagnosis of metastases was not confirmed by pleural
biopsy and/or surgical exploration in one of patients
since the physical condition of the patient was not
suitable for these procedures. However, CTs of this
patient indicated a marked increase in the size of the
pleural effusions. Histological and/or cytological
confirmation of the metastatic disease was obtained
by biopsy in another patient. In one patient,
pneumothorax (without any radiograpic indication
of nodule) was found in the first presentation.
Hilar lymphadenopathy was the only feature of
metastasis in one patient. In this case, diagnosis
was made by mediastinoscopy.
Discussion
In our study, 90 out of 400 patients (23%) with
extremity sarcoma developed pulmonary metastases
during a 10-year follow-up period. The predilection
for pulmonary metastases in patients with extremity
sarcoma has also been shown in other studies.
3,7–9 In
an earlier study reviewing 211 patients with high-
grade extremity sarcoma, a recurrence rate of 31%,
including both local and distant metastases, was
reported.
3 In that study, pulmonary metastases alone
represented 70% of these sites, with an incidence of
21% in those patients with high-grade extremity
STS. In another investigation, 135 of 716 (19%)
patients of extremity sarcoma were found to have
pulmonary metastases.
4 The findings of our study
are in close agreement with the results of earlier
reports.
3,4
The time from presentation to development of
pulmonary metastases is difficult to ascertain from
the literature. In our study, more than 75% of
patients developed lung metastases within 1 year
after presentation.
The probability of the occurrence of pulmonary
metastases was significantly influenced by the histo-
pathological type of the tumour.
5,10,11 In a study of
91 patients with extremity STS, those with MFH,
malignant schwannoma and spindle cell sarcoma had
an increased incidence of pulmonary metastases.
8 In
our study, histological analysis of primary lesions
indicates that pulmonary metastases arise most
commonly in patients with synoviosarcoma and
osteosarcoma. Our study also suggested a relation-
ship between metastases-free intervals and disease
grade. A longer metastases-free interval is seen in
lower grade tumours. Since the majority of patients
developed lung metastases within 1 year, the optimal
follow-up for lung imaging should be chest X-rays
and CT scanns every 4 months during the first 2 years
after diagnosis.
Table 4. Manifestation of metastatic lung disease in 90 patients as revealed on computed tomography
Manifestation n %
Solitary nodule 11 12.2
Bilateral multiple nodules 43 47.7
Pulmonary parenchymal mass 10 11.1
Pleural effusionþpulmonary parenchymal mass 8 8.8
Pleural effusion 2 2.2
Pulmonary parenchymal massþmultiple nodules 10 11.1
Pulmonary parechymal massþmultiple nodulesþpleural effusion 4 4.4
Hilar lymphadenopathy 1 2.2
Pneumothorax 1 1.1
Total 90 100%
66 N. Songu ¨r et al.There are only a few anectodal reports in the
literature describing the radiographic appearances of
the pulmonary metastases from extremity sarcoma.
In general, these studies suggest that the pulmonary
metastases present as solitary or multiple pulmonary
nodules.
12–14 In our study, the most frequent
(47.7%) manifestation of metastasis on CT was
multiple pulmonary nodules. This finding is com-
parable to the results reported in earlier studies.
12–15
The pulmonary nodules were concentrated mainly
in the lower lobes of the lung as subpleural or
parenchymatous. In patients with STS, most pul-
monary nodules were subpleural, whereas patients
with osteogenic sarcoma had nodules that were
paranchymatous or subpleural and often ossified.
A sharp and well-circumscribed margin was usually
seen in these nodules. Considering that sarcoma
patients have higher risk of metastases, in cases
where clinical proof for a second primary tumour was
missing or ambiguous, the presence of more than
one parenchymal nodule was considered metastatic.
This pattern of pulmonary metastasis is not unique
to patients with extremity sarcoma. Metastases
from hypernephromas, testicular, breast, cervical
and endometrial carcinomas may all have a similar
pattern. In the current study, it was noted that all of
the solitary metastases were detected in the patients
with extremity STS. Our study demonstrates that
patients with extremity sarcomas have also different
radiological appearances, such as pulmonary mass,
pleural effusion, hilar lymphadenopathy and pneu-
mothorax. To our knowledge, this is one of the
largest studies focusing on all radiological features of
the pulmonary metastases of extremity sarcomas.
Another notable finding concerns the state of the
metastases. At the time of the initial assesment, all
lesions are metastatic and active, but they may
disappear subsequently or become totally necrotic
with chemotheraphy.
16 Although complete necrosis
or disappearance of the metastatic nodule(s) is
possible, this did not occur in our study. Since our
study was conducted in a retrospective manner,
pathological confirmation of suspicious lesions,
especially multiple nodules on chest CTs or cytolo-
gical proof of pleural effusions were not always
present. However, follow-up of all lesions seen on
CTs was performed.
In conclusion, in our study, we found an incidence
of lung metastases of approximately 23% in patients
with extremity sarcomas. Most patients developed
lung metastases within 1 year after presentation.
Metastases-free intervals were significantly shortened
as the grade of the disease increased. Radiographi-
cally, pulmonary metastases in patients with extrem-
ity sarcomas may present as solitary or multiple
nodules most commonly located in the peripheral
and lower zones of the lung. However, it should also
be noted that a substantial number of patients may
present with radiological appearances of lesions that
are neither solitary nor nodular.
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